Xarelto Lawsuit Plaintiffs See Another Bellwether Preparation Deadline Approaching In June

March 23, 2016 – – BloodThinnerHelp.com reports on a quickly approaching deadline provided in the Honorable Judge Eldon Fallon’s 3rd Case Management Order for lawsuits involved in Xarelto MDL No. 2592. The order required that “The parties are to meet and confer before June 10, 2016, to propose a Case Management Order to address the selection method for bellwether plaintiff cases for trial. The parties will submit the proposed Case Management Order to the Court by July 1, 2016.”

Case management selection preparations began at the end of 2015 and early 2016, when plaintiffs, defendants, and the court worked together to select cases to form a bellwether pool of 40 complaints. From these 40, the judge requested that 4 move on to be heard in bellwether trials, and this is likely to take place in February of 2017. Bellwether trials are designed to give everyone involved in litigation a better idea of how juries might respond to certain testimony and evidence.

Xarelto lawsuits have been steadily increasing in number for 5 years now when plaintiffs from across the U.S. stepped forward to file complaints regarding new-generation blood thinner Xarelto against manufacturers Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson corporation) and Bayer AG. Today, thousands of plaintiffs have become involved, all who share strikingly similar allegations claiming that the anticoagulant drug puts users at increased risk for sudden and dangerous bleeding episodes, some of which, according to plaintiffs filing lawsuits on behalf of deceased family members, have proven fatal.

Xarelto has also been the recipient of two “black box” warnings from the U.S. Food and Drug Administration (FDA). These warnings informed patients using the drug that if they discontinued use of the drug too suddenly, they were at significantly higher risk for the development of blood clots, epidural or spinal hematoma, or deep vein thrombosis.

Additional studies conducted on the drug have shown a potential risk for eye and stomach bleeds during a transition from traditional blood thinner use to Xarelto use. Plaintiffs involved in current lawsuits have named a variety of side effects that they claim the drug has caused, including strokes, pulmonary embolism, heart attacks, brain hemorrhages, gastrointestinal bleeding, rectal bleeding, eye and stomach bleeds, epidural hematoma, and death. Lawsuits filed in federal courts from around the nation were transferred to a single court in Eastern Louisiana to form MDL 2592 by the U.S. Judicial Panel on Multidistrict Litigation. These cases currently number more than 2,800 and are joined by another group of over 600 cases which has been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.

Because additional lawsuits are expected to continue being filed, Attorney Joseph Osborne is working to help ensure that patients who have used Xarelto and believe that they have suffered from medical problems as a result of the drug will be provided the important opportunity to explore their legal rights in full. Affected patients may be entitled to substantial compensation gained through legal action. To better assist those looking to pursue justice, Attorney Osborne is offering free legal consultations to affected individuals at this time.

To request additional information, or to ask questions about Xarelto lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008840